RhumbLine Advisers
GNCA

RhumbLine Advisers’s Genocea Biosciences, Inc. GNCA Stock Holding History

RhumbLine Advisers’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,125
Closed -$35K – 2962
2018
Q1 		$35K Buy
4,125
+1,079
+35% +$8.96K ﹤0.01% 2804
2017
Q4 		$28K Sell
3,046
-736
-19% -$7.4K ﹤0.01% 2826
2017
Q3 		$44K Buy
3,782
+32
+0.9% +$1.22K ﹤0.01% 2895
2017
Q2 		$157K Buy
+3,750
New +$181K ﹤0.01% 2826
2016
Q2 		– Sell
-2,492
Closed -$154K – 3054
2016
Q1 		$154K Hold
2,492
– – ﹤0.01% 2812
2015
Q4 		$105K Buy
2,492
+427
+21% +$20.3K ﹤0.01% 2947
2015
Q3 		$113K Buy
2,065
+194
+10% +$19.2K ﹤0.01% 2928
2015
Q2 		$206K Buy
+1,871
New +$174K ﹤0.01% 2880

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers's GNCA Position: Q2 2018 in Review

RhumbLine Advisers sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2018, closing a stake of 4,125 shares — an estimated $35K sold.

RhumbLine Advisers first reported a position in GNCA in Q2 2015 and held it in 8 quarters. The position peaked at $206K in Q2 2015. 54 funds tracked by Wall St. Rank hold GNCA as of Q2 2018.

  • RhumbLine Advisers reported no remaining Genocea Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
  • RhumbLine Advisers sold 4,125 Genocea Biosciences, Inc. shares in Q2 2018, an estimated $35K.
  • RhumbLine Advisers first reported a position in Genocea Biosciences, Inc. in Q2 2015 and held it in 8 quarters.
  • RhumbLine Advisers's Genocea Biosciences, Inc. position peaked at $206K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2018.

Based on RhumbLine Advisers's 13F filing for Q2 2018, filed 6 Aug 2018.